Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Search
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
TCO patient podcasts
From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.
Agreement-to-acquire-NBE-Therapeutics
Boehringer Ingelheim to acquire NBE-Therapeutics to significantly enhance cancer pipeline portfolio with antibody-drug conjugates.
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
Our Innovation Strategy
A deep understanding of disease, identifying relevant mechanisms and choosing therapeutic modalities to address them is the core of our innovation strategy
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Dr. Hsing-Jung Chen-Engerer
Prioritizing development with Dr. Hsing-Jung Chen-Engerer
Prof. Eric Haaksma
Prof. Eric Haaksma on transforming lives for generations
Liliana Montano
Liliana Montano on constant innovation
Human Health
Human Health
Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
SIRPα antagonist
SIRPα antagonist
Ivan Blanarik Therapeutic Area Head Respiratory
Ivan Blanarik, Therapeutic Area Head Respiratory at Boehringer Ingelheim
CD137/FAP agonist
CD137/FAP agonist
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Boehringer Ingelheim invests in precision cancer treatments
Boehringer Ingelheim Venture Fund invests in Synthetica as part of its commitment to advancing innovative, next-generation cancer therapies
Biberach
The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Taking Cancer on Through Flavour
Recipes developed specifically for people living with cancer. Contributions from a chef, a dietitian, and a cancer survivor.